Aligos Therapeutics(ALGS)
$2.16-0.41 (-15.95%)
ALGS
Aligos Therapeutics financials statements
$2.16
At close:-0.41 (-15.95%)
Want to see ALGS full AI Analyst Report?
Aligos Therapeutics (ALGS) Ratios
500 Followers
Aligos Therapeutics Ratios
ALGS's free cash flow for Q3 2026 was $1.32M. For the 2026 fiscal year, ALGS's free cash flow was decreased by $-127.00K and operating cash flow was $1.45M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.90 | 2.86 | 5.90 | 4.03 | 5.25 |
| Quick Ratio | 3.90 | 2.86 | 5.90 | 4.03 | 5.25 |
| Cash Ratio | 0.86 | 1.70 | 5.68 | 2.46 | 4.80 |
| Solvency Ratio | -0.66 | -1.30 | -1.42 | -2.16 | -2.46 |
| Operating Cash Flow Ratio | -3.89 | -3.71 | -3.30 | -2.40 | -2.97 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 47.87M | $ -36.93M | $ 81.64M | $ 90.75M | $ 153.79M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.06 | 0.12 | 0.07 | 0.09 | 0.06 |
| Debt-to-Equity Ratio | 0.10 | -0.29 | 0.12 | 0.12 | 0.08 |
| Debt-to-Capital Ratio | 0.09 | -0.41 | 0.11 | 0.11 | 0.07 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.65 | -2.42 | 1.65 | 1.41 | 1.27 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.53 | 1.34 | 0.45 | 0.29 | 0.36 |
| Net Debt to EBITDA | 0.57 | 0.22 | 1.46 | 0.73 | 1.38 |
| Profitability Margins | |||||
| Gross Profit Margin | 57.46% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | -1092.36% | -3317.62% | -567.50% | -701.66% | -2943.82% |
| EBITDA Margin | -1049.82% | -3251.15% | -547.74% | -675.24% | -2857.15% |
| Operating Profit Margin | -4024.93% | -2259.92% | -567.50% | -701.66% | -2943.82% |
| Pretax Profit Margin | -1092.36% | -3317.62% | -559.50% | -689.87% | -2940.79% |
| Net Profit Margin | -1106.72% | -3326.01% | -564.61% | -690.63% | -2944.07% |
| Continuous Operations Profit Margin | -1106.72% | -3326.01% | -564.61% | -690.63% | -2944.07% |
| Net Income Per EBT | 101.31% | 100.25% | 100.92% | 100.11% | 100.11% |
| EBT Per EBIT | 27.14% | 146.80% | 98.59% | 98.32% | 99.90% |
| Return on Assets (ROA) | -27.33% | -187.19% | -57.86% | -65.47% | -54.52% |
| Return on Equity (ROE) | -45.18% | 452.87% | -95.22% | -92.44% | -69.47% |
| Return on Capital Employed (ROCE) | -130.74% | -184.37% | -69.05% | -85.93% | -65.33% |
| Return on Invested Capital (ROIC) | -123.88% | -172.06% | -67.34% | -83.61% | -64.38% |
| Return on Tangible Assets | -27.33% | -187.19% | -57.86% | -65.47% | -54.52% |
| Earnings Yield | -26.26% | -52.57% | -21.23% | -9.44% | -1.09% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.23 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.44 | 0.54 | 1.58 | 1.11 | 0.29 |
| Asset Turnover | 0.02 | 0.06 | 0.10 | 0.09 | 0.02 |
| Working Capital Turnover Ratio | 0.04 | 0.05 | 0.14 | 0.10 | 0.02 |
| Cash Conversion Cycle | -1562.83 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 1562.83 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -8.35 | -12.89 | -3.18 | -1.86 | -2.90 |
| Free Cash Flow Per Share | -8.39 | -12.91 | -3.18 | -1.88 | -2.92 |
| Dividend Paid and CapEx Coverage Ratio | -188.79 | -621.10 | -4157.74 | -84.19 | -129.67 |
| Capital Expenditure Coverage Ratio | -188.79 | -621.10 | -4157.74 | -84.19 | -129.67 |
| Operating Cash Flow Coverage Ratio | -15.71 | -9.64 | -7.09 | -6.31 | -8.00 |
| Operating Cash Flow to Sales Ratio | -37.74 | -20.47 | -5.09 | -5.71 | -26.53 |
| Free Cash Flow Yield | -90.03% | -32.40% | -19.14% | -7.90% | -0.99% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3.80 | -1.90 | -4.71 | -10.59 | -92.16 |
| Price-to-Sales (P/S) Ratio | 42.14 | 63.27 | 26.59 | 73.13 | 2713.26 |
| Price-to-Book (P/B) Ratio | 1.72 | -8.61 | 4.48 | 9.79 | 64.02 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.11 | -3.09 | -5.23 | -12.66 | -101.47 |
| Price-to-Operating Cash Flow Ratio | -1.12 | -3.09 | -5.23 | -12.81 | -102.26 |
| Price-to-Earnings Growth (PEG) Ratio | 0.04 | -0.00 | -0.08 | 0.35 | -73.27 |
| Enterprise Value Multiple | -3.45 | -1.72 | -3.39 | -10.10 | -93.58 |
| Enterprise Value | 79.07M | 220.96M | 288.33M | 948.23M | 11.65B |
| EV to EBITDA | -3.45 | -1.72 | -3.39 | -10.10 | -93.58 |
| EV to Sales | 36.17 | 56.01 | 18.57 | 68.18 | 2673.72 |
| EV to Free Cash Flow | -0.95 | -2.73 | -3.65 | -11.80 | -99.99 |
| EV to Operating Cash Flow | -0.96 | -2.74 | -3.65 | -11.94 | -100.77 |
| Tangible Book Value Per Share | 5.42 | -4.62 | 3.70 | 2.43 | 4.64 |
| Shareholders’ Equity Per Share | 5.42 | -4.62 | 3.70 | 2.43 | 4.64 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.01 | -0.00 | -0.01 | -0.00 | -0.00 |
| Revenue Per Share | 0.22 | 0.63 | 0.62 | 0.33 | 0.11 |
| Net Income Per Share | -2.45 | -20.94 | -3.52 | -2.25 | -3.22 |
| Tax Burden | 1.01 | 1.00 | 1.01 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.99 | 0.98 | 1.00 |
| Research & Development to Revenue | 31.77 | 17.81 | 4.70 | 6.12 | 23.89 |
| SG&A to Revenue | 9.48 | 5.79 | 1.97 | 1.90 | 6.54 |
| Stock-Based Compensation to Revenue | 2.31 | 2.14 | 0.81 | 1.06 | 3.09 |
| Income Quality | 3.41 | 0.62 | 0.90 | 0.83 | 0.90 |
Currency in USD
